SCHEMBL3347374

SCHEMBL3347374

COC(=O)c1cccc2cc(-c3ccc(OC)cc3C34CC5CC(CC(C5)C3)C4)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 3/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A2 P23975 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NR1I2 O75469 1/20 0.42
LMNA P02545 1/20 0.42
PGR P06401 1/20 0.42
RARA P10276 1/20 0.42
HSPD1 P10809 1/20 0.42
RARB P10826 1/20 0.42
RARG P13631 1/20 0.42
GOT1 P17174 1/20 0.42
GLRA1 P23415 1/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322256 0.91 KMT2A (0.48) KDM4EMEN1KMT2ANR1I2LMNA
SCHEMBL3350681 0.89 SLC6A3 (0.42) SLC6A3SLC6A4SLC6A2KDM4EMEN1
SCHEMBL851508 0.83 RARA (0.60) SLC6A3SLC6A4SLC6A2KDM4EMEN1
SCHEMBL3350688 0.82 RARB (0.54) SLC6A3SLC6A4SLC6A2KDM4EMEN1
SCHEMBL9300831 0.77 RARB (0.69) KDM4EMEN1KMT2ANR1I2LMNA
SCHEMBL5613344 0.76 PPARG (0.44) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL2237855 0.75 MTNR1A (0.56) SLC6A3SLC6A4SLC6A2KDM4ECYP1A2
SCHEMBL3322258 0.73 RARB (0.67) KDM4EMEN1KMT2ANR1I2LMNA
SCHEMBL29222875 0.73 WDR5 (0.45) KDM4ECYP2D6CYP2C9MEN1KMT2A
SCHEMBL6571522 0.71 RARB (0.54) KDM4EMEN1KMT2ANR1I2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896399-B1 BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES SIGMA TAU IND FARMACEUTI (IT) 2010-11-17 EP disclosed
US-7728039-B2 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-06-01 US disclosed
US-20080319082-A1 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-12-25 US disclosed
EP-1896399-A1 BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2008-03-12 EP disclosed
WO-2007000383-A1 BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319082-A1 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives VHL, ARNT, AHR SLC6A3 2405/4885SLC6A4 2101/4885SLC6A2 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.